Ignite Creation Date:
2024-05-06 @ 8:01 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06229366
Status:
RECRUITING
Last Update Posted:
2024-04-23
First Post:
2024-01-03
Brief Title:
Ac-225-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
Sponsor:
POINT Biopharma a wholly owned subsidiary of Eli Lilly and Company
Organization:
POINT Biopharma a wholly owned subsidiary of Eli Lilly and Company
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-03-26
Start Date Type:
ACTUAL
Primary Completion Date:
2027-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-03
Completion Date Type:
ESTIMATED
First Submit Date:
2024-01-03
First Submit QC Date:
January 19 2024
Study First Post Date:
2024-01-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-09
Last Update Post Date:
2024-04-23
Last Update Post Date Type:
ACTUAL